

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to: www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	12
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	25
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	40
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	44
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	47
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

United States (Canada and United States)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	0.67	0.96	1.34
Year of IDU prevalence estimate	2002		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	8.74	15.57	22.4
Year of HIV prevalence among IDU estimate	2003		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	205 974 795 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	1 380 000	1 979 500	2 760 000
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	120 612	308208	618240

1. Needle and syringe programs (NSPs)

NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other NSP indicators
When were NSPs first introduced?	
Reference	
Are needles and syringes available for purchase from pharmacies?	Yes
Most recent year of documentation	2008
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.

NSP 2: Number of NSP sites

Data reported	186 SEPs known to North American Syringe Exchange Network including District of Columbia and Puerto Rico (NASEN)		
Year of reported data	2007		
Reference	Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." <i>Addiction</i> 104.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	186		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	0.07	0.09	0.14

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported	Needles and syringes available for purchase from pharmacies but number of sites not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	2002		
General population 15-64 years of age at year of reported data	205 974 795 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 380 000	1 979 500	2 760 000
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data	(source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	NSP present but number not known		
Year of reported data	2007		
Reference	Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." <i>Addiction</i> 104.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	NK	NK	NK

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	NSP present but number not known		
Year of reported data	2007		
Reference	Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." <i>Addiction</i> 104.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	NK	NK	NK

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	29 500000 syringes exchanged by 130 SEPs		
Year of reported data	2007		
Reference	Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." <i>Addiction</i> 104.		
Adjustments	Assumed average distribution from these 130 sites is same as average for total 186 known sites		
Final/Adjusted data (to be used as indicator numerator)	42 200 000		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	15.44	21.5	30.88

NSP: All documents reviewed

- AIDS project management group (2006). Proceedings - APMG satellite session on coverage of harm reduction programs.
- American Pharmaceutical Association (2002). Preventing blood-borne infections through pharmacy syringe sales and safe community syringe disposal. *Journal of the American Pharmaceutical Association*. 42.
- AVERT. (2008). "HIV prevention around the world." Retrieved 30 November, 2008, from <http://www.avert.org/global-hiv-prevention.htm>
- AVERT. (2008). "Needle exchanges." Retrieved 30 November, 2008, from <http://www.avert.org/needle-exchange.htm>
- AVERT. (2008). "Why is HIV prevention needed in America?" Retrieved 30 November, 2008, from <http://www.avert.org/hiv-prevention->
- Bluthenthal, R. N. and A. H. Kral (2008). Recommended preventive service utilization among IDUs who do and do not use SEPs.
- Bluthenthal, R. N., G. Ridgeway, et al. (2007). "Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users." *Addiction* 102(4): 638-46.
- Bluthenthal, R. N., M. R. Malik, et al. (2004). "Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities.[see comment]." *Addiction* 99(9): 1136-46.
- Bluthenthal, R., K. Heinzerling, et al. (2008). "Approval of Syringe Exchange Programs in California: Results From a Local Approach to HIV Prevention." *American Journal of Public Health* 98(2): 278.
- Boutwell, A. and J. D. Rich (2004). "Syringe access for injection drug users in Rhode Island." *Medicine & Health, Rhode Island* 87(1): 15-6.
- Centers for Disease Control & Prevention (2007). "Syringe exchange programs--United States, 2005." *MMWR - Morbidity & Mortality Weekly Report* 56(44): 1164-7.
- Centers for Disease Control and Prevention (2005). "Update: syringe exchange programs--United States, 2002." *MMWR - Morbidity & Mortality Weekly Report* 54(27): 673-6.
- Centers for Disease Control and Prevention (2005). Access to Sterile Syringes. Atlanta, CDC.
- Centers for Disease Control and Prevention (2005). Fact Sheet: State and Local Policies Regarding IDUs' Access to Sterile Syringes. Atlanta,
- Centers for Disease Control and Prevention (2007). Syringe Exchange Programs - United States, 2005. *MMWR Weekly Centers for Disease Control and Prevention*. 56: 1164-1167.
- Centers for Disease Control and Prevention (2007). Syringe exchange programs - United States, 2005. *Morbidity and Mortality Weekly Report*. Atlanta. 56(44): 1164-1167.
- Centers for Disease Control and Prevention (CDC) (2007). Syringe exchange programs --- United States, 2005. *Morbidity and Mortality Weekly Report*,. 56(44): 1164-1167.
- Cleland, C. M., S. Deren, et al. (2007). "Syringe disposal among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program." *Health Education & Behavior* 34(2): 390-403.
- Crary, D. (2008) "Groups Seek End to Needle-Exchange Ban."
- Deibert, R. J., G. Goldbaum, et al. (2006). "Increased access to unrestricted pharmacy sales of syringes in Seattle-King County, Washington: structural and individual-level changes, 1996 versus 2003." *American Journal of Public Health* 96(8): 1347-53.
- Des Jarlais, D. C. (2006). "Mathilde Krim, amfAR, and the prevention of HIV infection among injecting drug users: a brief history." *AIDS Patient Care & Stds* 20(7): 467-71.
- Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." *Addiction* 104.
- Des Jarlais, D. C., T. Perlis, et al. (2004). "'Informed altruism' and 'partner restriction' in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001." *Journal of Acquired Immune Deficiency Syndromes: JAIDS* 35(2): 158-66.
- Des Jarlais, D. C., T. Perlis, et al. (2005). "Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001." *AIDS* 19 Suppl 3: S20-5.
- Des Jarlais, D. C., Z. Sloboda, et al. (2006). "Diffusion of the D.A.R.E and syringe exchange programs." *American Journal of Public Health* 96(8):
- Des Jarlais, D., C. McKnight, et al. (2004). "Public funding of US Syringe Exchange Programs." *Journal of Urban Health* 81(1): 118-121.
- DeSimone, J. (2005). "Needle exchange programs and drug infection behavior." *Journal of Policy Analysis & Management* 24(3): 559-77.

NSP: All documents reviewed

- Disney, E., M. Kidorf, et al. (2006). "Psychiatric comorbidity is associated with drug use and HIV risk in syringe exchange participants." *Journal of Nervous & Mental Disease* 194(8): 577-83.
- Downing, M., T. H. Riess, et al. (2005). "What's community got to do with it? Implementation models of syringe exchange programs." *AIDS Education & Prevention* 17(1): 68-78.
- Edlin, B., T. Kresina, et al. (2005). "Overcoming Barriers to Prevention, Care, and Treatment of Hepatitis C in Illicit Drug Users." *Clinical Infectious Diseases* 40(S5): 276-285.
- Harm Reduction Coalition (2008). *Syringe Exchange Program Technical Assistance Newsletter*, Harm Reduction Coalition. 1(1).
- Harm Reduction Coalition. "HIV." Retrieved 7 Nov, 2008, from <http://www.harmreduction.org/article.php?list=type&type=48>.
- Harm Reduction Coalition. (2008). "California Needle Exchange List." Retrieved 15/12/2008, from
- Harm Reduction Coalition. (2008). "Washington." Retrieved 15/12/2008, from <http://www.harmreduction.org/article.php?id=226>.
- Harm reduction Coalition. (2008, 19/10/2007). "CA law authorizes use of state funds to purchase syringes." Retrieved 15/12/2008, from <http://www.harmreduction.org/article.php?id=637>.
- Harris, Z. K. (2006). "Efficient allocation of resources to prevent HIV infection among injection drug users: the Prevention Point Philadelphia (PPP) needle exchange program." *Health Economics* 15(2): 147-58.
- HIV education and prevention services branch Office of AIDS Department of health services California (2007). Request for applications Number 2007-09 Statewide HIV/AIDS/STD education and prevention programs.
- Human Rights Watch (2004). "U.S.: needle-exchange law helps to combat AIDS." Retrieved 30th November, 2008, from <http://www.hrw.org/en/news/2004/06/23/us-needle-exchange-law-helps-combat-aids>.
- Huo, D. and L. J. Ouellet (2007). "Needle exchange and injection-related risk behaviors in Chicago: a longitudinal study." *Journal of Acquired Immune Deficiency Syndromes: JAIDS* 45(1): 108-14.
- Huriaux, E. HIV Prevention Section, AIDS Office, San Francisco Department of Public Health. Personal Communication: Response to request for information on HIV services for injecting drug users. San Francisco, United States, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 January 2009.
- International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.
- Islam, M. M. and K. Conigrave (2007). "Assessing the role of syringe dispensing machines and mobile van outlets in reaching hard-to-reach and high-risk groups of injecting drug users (IDUs): a review." *Harm Reduction Journal* 4(1): 14.
- Jacobs, F. M. (2007). "DHSS approves state's first syringe exchange programs." *New Jersey Nurse* 37(5): 12.
- Knight, C. A., Des Jarlais, D.C., Eigo, K., Krim, M., Auerbach, J., Solberg, A. and Garfein, R.S. (2005). Update: Syringe exchange programs - United States, 2002.
- Ksobiech, K. (2003). "A Meta-Analysis of Needle Sharing, Lending, and Borrowing Behaviors of Needle Exchange Program Attenders." *AIDS Education and Prevention* 15(3): 257-268.
- Latkin, C. A., M. A. Davey, et al. (2006). "Social context of needle selling in Baltimore, Maryland." *Substance Use & Misuse* 41(6-7): 901-13.
- Lifepoint (2005). *Outreach and syringe program guidelines and operating procedures*
- Lorvick, J., R. N. Bluthenthal, et al. (2006). "Secondary syringe exchange among users of 23 California syringe exchange programs." *Substance Use & Misuse* 41(6-7): 865-82.
- Mark, H. D., J. Nanda, et al. (2006). "Profiles of self-reported HIV-risk behaviors among injection drug users in methadone maintenance treatment, detoxification, and needle exchange programs." *Public Health Nursing* 23(1): 11-9.
- Moore, G., P. McCarthy, et al. (2004). A review of harm reduction approaches in Ireland and evidence from the international literature. Dublin, National Advisory Committee on Drugs.
- New York City Commission (2005). *Report of the New York City Commission on HIV/AIDS: Recommendations to make NYC a national and global model for HIV/AIDS prevention, treatment, and care*. New York, New York City Commission: 51.
- Office of AIDS California Department of public health (2008). *Pharmacy sale of syringes in California*.
- Office of AIDS California Department of public health (2008). *Syringe exchange programs in California: An overview*.
- Office of AIDS California Department of public health (2009). *Syringe access: Authorized SEPs and pharmacy sales in California*.

NSP: All documents reviewed

Prevention Point Philadelphia (2008). Quarterly Service Data.

Rich, J. D., J. W. Hogan, et al. (2007). "Lower syringe sharing and re-use after syringe legalization in Rhode Island." *Drug & Alcohol Dependence* 89(2-3): 292-7.

Riehman, K. S., A. H. Kral, et al. (2004). "Sexual relationships, secondary syringe exchange, and gender differences in HIV risk among drug injectors." *Journal of Urban Health* 81(2): 249-59.

Rose, V. (2007). "Expanding access to syringes." *Focus: a Guide to AIDS Research* 22(3): 1-5.

Rose, V., H. F. Raymond, et al. (2006). "Assessing the feasibility of harm reduction services for MSM: the late night breakfast buffet study." *Harm Reduction Journal* 3(1): 29.

San Francisco Department of Public Health (2008). Adult Viral Hepatitis Resource Guide. San Francisco.

Sendziuk, P. (2007). "Harm reduction and HIV-prevention among injecting drug users in Australia: an international comparison." *Canadian Bulletin of Medical History/Bulletin Canadien d'Histoire de la Medecine* 24(1): 113-29.

Shaw, S. J. (2006). "Public citizens, marginalized communities: the struggle for syringe exchange in Springfield, Massachusetts." *Medical Anthropology* 25(1): 31-63.

Sherman, S. G. (2006). "Critical condition facing needle exchange programs: the politics of science." *Substance Use & Misuse* 41(6-7): 827-9.

Shrestha, S., M. W. Smith, et al. (2006). "Multiperson use of syringes among injection drug users in a needle exchange program: a gene-based molecular epidemiologic analysis." *Journal of Acquired Immune Deficiency Syndromes: JAIDS* 43(3): 335-43.

Stancliff, S., B. Agins, et al. (2003). "Syringe access for the prevention of blood borne infections among injection drug users." *BMC Public Health*

Stozek, M. A., L. E. Taylor, et al. (2004). "Prescribing syringes to injection drug users with HIV: an important clinical and public health tool." *Journal of the Association of Nurses in AIDS Care* 15(2): 59-63.

Strathdee, S. (2004). "Needle-exchange programs and the prevention of HIV infection. Interview by Vicki Glaser." *AIDS Patient Care & Stds* 18(7):

Strike, C., K. Leonard, et al. (2006). Ontario needle exchange programs: Best practice recommendations. Ontario Needle Exchange Coordinating Committee. Toronto.

Strike, C., Leonard, L., Millson, M., Anstice, S., Berkeley, N., & Medd, E (2006). Ontario Needle Exchange Programs: Best Practice Recommendations. Ontario, Ontario Needle Exchange Coordinating Committee: 266.

Tempalski, B. (2007). "Placing the dynamics of syringe exchange programs in the United States." *Health & Place* 13(2): 417-31.

Tempalski, B., H. L. Cooper, et al. (2008). "Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug." *International Journal of Drug Policy* 19 Suppl 1: S47-58.

Tempalski, B., P. Flom, et al. (2007). "Social and Political Factors Predicting the Presence of Syringe Exchange Programs in 96 US Metropolitan Areas." *American Journal of Public Health* 97(3): 437.

Tomolillo, C. M., L. J. Crothers, et al. (2007). "The damage done: a study of injection drug use, injection related abscesses and needle exchange regulation." *Substance Use & Misuse* 42(10): 1603-11.

Trigg, B. G. (2005) Corrections: the next challenge for harm reduction in the U.S. 36

Welton, A., K. Adelberger, et al. (2004). "Optimal placement of syringe-exchange programs." *Journal of Urban Health* 81(2): 268-77.

Wodak, A. (2005). "The US war on harm reduction: fixing policy on intelligence and facts." *Harm Reduction Journal* 2(1): 14.

2. Opioid substitution treatment (OST)**OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other OST indicators
When was agonist OST first available?	
Reference	

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other OST indicators
When was MMT first available?	
Reference	

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other OST indicators
When was BMT first available?	
Reference	

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	
Comments	
Most recent year of documentation	
Reference	
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	
Comments	
Year	
Reference	
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	16-24 mg
Comments	Daily maintenance dose recommended under the US national clinical guidelines for buprenorphine treatment
Year	2005
Reference	Carrieri, M. P., L. Amass, et al. (2006). "Buprenorphine use: the international experience." Clinical Infectious Diseases 43 Suppl 4: S197-215.
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	1433 facilities licensed, certified or accredited to offer MMT/BMT		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	1433		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	0.52	0.73	1.05

OST 8: Number of sites providing MMT

Data reported	1206 licensed methadone treatment programs		
Year of reported data	2009		
Reference	Division of Pharmacologic Therapies U.S. Department of Health and Human Services. (2009). "Opioid treatment program directory." Retrieved 8 December, 2009, from http://dpt2.samhsa.gov/treatment/directory.aspx .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	1206		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	207 873 046 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 392 500	1 997 500	2 785 500
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	0.43	0.60	0.87

OST 9: Number of sites providing BMT

Data reported	BMT available but number not known (buprenorphine can be dispensed either through an OST or by a private physician who has been waived to provide office-based treatment)		
Year of reported data	2009		
Reference	Reckitt Benckiser (2009). Unpublished internal data. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 August 2009. Maxwell, J. Personal Communication: Feedback on the US country report. United States 2009. Received by the Reference Group to the UN on HIV & injecting drug use on 17 November 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	207 873 046 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 392 500	1 997 500	2 785 500
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

OST 11: Number of all clients in any OST at a single point in time

Data reported	253 475 clients in MMT/BMT on March 30, 2007		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	253 475		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	9.27	12.93	18.55

OST 12: Number of all clients in MMT at a single point in time

Data reported	253 475 clients in OST 168 405 clients in BMT		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville. Reckitt Benckiser (2009). Unpublished internal data. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 August 2009.		
Adjustments	Assumed MMT & BMT client groups are mutually exclusive OST & BMT counts are for 2007 and 2009 respectively calculated an estimate for 2008 MMT count by subtracting BMT count from total OST count and assumed number of clients in BMT were same in 2007 as reported in 2009		
Final/Adjusted data (to be used as indicator numerator)	85 070		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	3.11	4.34	6.23

OST 13: Number of all clients in BMT at a single point in time

Data reported	Clients currently in BMT, Mar 2009		
Year of reported data	2009		
Reference	Reckitt Benckiser (2009). Unpublished internal data. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 August 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	168 405		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	207 873 046 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 392 500	1 997 500	2 785 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	6.05	8.43	12.09

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville. Reckitt Benckiser (2009). Unpublished internal data. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 August 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2009		
Reference	Reckitt Benckiser (2009). Unpublished internal data. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 August 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	207 873 046 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 392 500	1 997 500	2 785 500
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	OST available but number of clients on OST not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	MMT available but number of clients not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville. Reckitt Benckiser (2009). Unpublished internal data. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 August 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	BMT available but number of clients not known		
Year of reported data	2009		
Reference	Reckitt Benckiser (2009). Unpublished internal data. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 August 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	207 873 046 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 392 500	1 997 500	2 785 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville. Reckitt Benckiser (2009). Unpublished internal data. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 August 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2009		
Reference	Reckitt Benckiser (2009). Unpublished internal data. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 August 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	207 873 046 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 392 500	1 997 500	2 785 500
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High

OST: All documents reviewed

Carrieri, M. P., L. Amass, et al. (2006). "Buprenorphine use: the international experience." *Clinical Infectious Diseases* 43 Suppl 4: S197-215.

Centers for Disease Control and Prevention (2002). *Policy Issues and Challenges in Substance Abuse Treatment*. Atlanta, CDC.

Chapleo, C. (2008). *Follow up coverage with methadone and buprenorphine internationally*. B. Mathers. Sydney.

Dolan, K., E. M. Khoei, et al. (2007). *Prisons and Drugs: A global review of incarceration, drug use and drug services*. The beckley foundation drug policy programme.

Executive Office of the President Office of the National Drug Control Policy (2006). *Inventory of State Substance Abuse Prevention and Treatment Activities and Expenditures*. Washington DC: 820.

Farrell, M., W. Ling, et al. (2005). *Effectiveness of drug dependence treatment in preventing HIV among injecting drug users*. Evidence for action technical papers, World Health Organization (WHO).

Heimer, R., H. Catania, et al. (2006). "Methadone maintenance in prison: Evaluation of a pilot program in Puerto Rico." *Drug and Alcohol Dependence* 83(2): 122-129.

Jurgens, R. (2007). *Interventions to address HIV in prisons: drug dependence treatments*. Evidence for action technical papers. Geneva, World Health Organisation (WHO).

Mark, H. D., J. Nanda, et al. (2006). "Profiles of self-reported HIV-risk behaviors among injection drug users in methadone maintenance treatment, detoxification, and needle exchange programs." *Public Health Nursing* 23(1): 11-9.

McNeely, J., J. Arnsten, et al. (2006). "Sterile syringe access and disposal among injection drug users newly enrolled in methadone maintenance treatment: a cross-sectional survey." *Harm Reduction Journal* 3(1): 8.

San Francisco Department of Public Health (2008). *Adult Viral Hepatitis Resource Guide*. San Francisco.

Substance Abuse and Mental Health Services Administration Office of Applied Studies (2007). *National Survey of Substance Abuse Treatment Services (N-SSATS): 2006*. Data on substance abuse treatment facilities. DASIS Series: S-39. Rockville.

Trigg, B. G. (2005) *Corrections: the next challenge for harm reduction in the U.S.* 36

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	1445 outpatient detoxification facilities 996 residential non-hospital detoxification facilities 884 hospital inpatient detoxification facilities		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments	Counts are not mutually exclusive		
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	12 705 clients receiving outpatient detoxification 7536 clients receiving detoxification in residential non-hospital facilities 6319 clients receiving detoxification in hospital inpatient facilities (30 March 2007)		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments	Assumed counts are mutually exclusive		
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)	26 560		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	0.01	0.01	0.02

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?			
Number of sites - data reported	1722 sites providing short-term residential treatment 2995 sites providing long-term residential treatment		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments	Counts are not mutually exclusive		
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data	203 946 878 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High

ODT 2.3: Number of all clients in residential rehabilitation

Data reported	24 171 clients in short-term residential treatment 72002 clients in long-term residential treatment (30 March 2007)		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments	Assumed counts are mutually exclusive		
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)	96 173		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	0.05	0.04	0.07

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	yes		
Number of sites - data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	25 333 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	25 333		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	205 974 795 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 380 000	1 979 500	2 760 000
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	9.18	12.80	18.36

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	205 974 795 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 380 000	1 979 500	2 760 000
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	205 974 795 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 380 000	1 979 500	2 760 000
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available	Unspecified		
Number of sites - data reported	13 648 drug treatment facilities [A subset of these facilities may provide OST only or only detoxification or only residential rehabilitation]		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	13 648		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High
	4.99	6.96	9.99

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported	Drug treatment available but number of IDUs in treatment not known		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported	595 459 clients receiving regular outpatient treatment 132 977 clients receiving intensive outpatient treatment 22 297 clients receiving outpatient day treatment/partial hospitalization 8484 clients receiving hospital inpatient treatment (30 March 2007)		
Year of reported data	2007		
Reference	Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)	759 217		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High
	0.28	0.39	0.56

ODT 6 - Drug treatment in prisons**ODT 6.1: Number of prison drug treatment sites**

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High

ODT: All documents reviewed

Centers for Disease Control and Prevention (2002). Policy Issues and Challenges in Substance Abuse Treatment. Atlanta, CDC.

Centers for Disease Control and Prevention (2007). Syringe Exchange Programs - United States, 2005. MMWR Weekly Centers for Disease Control and Prevention. 56: 1164-1167.

Des Jarlais, D. C., T. Perlis, et al. (2004). "'Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001." Journal of Acquired Immune Deficiency Syndromes: JAIDS 35(2): 158-66.

DeSimone, J. (2005). "Needle exchange programs and drug infection behavior." Journal of Policy Analysis & Management 24(3): 559-77.

Executive Office of the President Office of the National Drug Control Policy (2006). Inventory of State Substance Abuse Prevention and Treatment Activities and Expenditures. Washington DC: 820.

Farrell, M., W. Ling, et al. (2005). Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Evidence for action technical papers, World Health Organization (WHO).

Friedman, S. R., B. Tempalski, et al. (2007). "Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States of America." International Journal of Drug Policy 18(6): 475-485.

Friedman, S., B. Tempalski, et al. (2004). "Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users." Journal of Urban Health 81(3): 377-400.

Gorman, E. M., B.-D. Barr, et al. (1997). "Speed, Sex, Gay Men, and HIV: Ecological and Community Perspectives " Medical Anthropology Quarterly 11(4): 505-515

Lifepoint (2005). Outreach and syringe program guidelines and operating procedures

Mark, H. D., J. Nanda, et al. (2006). "Profiles of self-reported HIV-risk behaviors among injection drug users in methadone maintenance treatment, detoxification, and needle exchange programs." Public Health Nursing 23(1): 11-9.

Substance Abuse and Mental Health Services Administration (SAMHSA) (2006). Treatment episode data set (TEDS) Highlights - 2004. National admissions to substance abuse treatment services Rockville, MD, Substance Abuse and Mental Health Services Administration (SAMHSA) DHHS Publication No. (SMA) 06-4140

Substance Abuse and Mental Health Services Administration Office of Applied Studies (2007). National Survey of Substance Abuse Treatment Services (N-SSATS): 2006. Data on substance abuse treatment facilities. DASIS Series: S-39. Rockville.

Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.

4. HIV testing and counselling (T&C)**T&C 1: Availability of HIV T&C**

Is T&C available?	Yes
Most recent year of data	2008
Reference	See references for other VCT indicators

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported	HIV counselling and testing provided by 115 out of 130 SEPs reporting in a NASEN survey in 2007 3968 drug treatment facilities provide HIV testing in 2007		
Year of reported data	2007		
Reference	Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." <i>Addiction</i> 104. Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments	Assumed SEPs not reporting in NASEN survey do not provide HIV counselling and testing		
Final/Adjusted data (to be used as indicator numerator)	4083		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High
	1.49	2.08	2.99

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	VCT available but number not known		
Year of reported data	2007		
Reference	Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." <i>Addiction</i> 104. Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44. Rockville.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	
Reference	
Data reported for both male and female IDUs	
Adjustments	
Final/Adjusted data	
Data reported for male IDUs	
Adjustments	
Final/Adjusted data	
Data reported for female IDUs	
Adjustments	
Final/Adjusted data	

T&C: All documents reviewed

Altice, F. L., A. Marinovich, et al. (2005). "Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection." *Journal of Urban Health* 82(2): 312-26.

Bluthenthal, R., K. Heinzerling, et al. (2008). "Approval of Syringe Exchange Programs in California: Results From a Local Approach to HIV Prevention." *American Journal of Public Health* 98(2): 278.

Centers for Disease Control & Prevention (2007). "Syringe exchange programs--United States, 2005." *MMWR - Morbidity & Mortality Weekly Report* 56(44): 1164-7.

Centers for Disease Control and Prevention (2005). "Update: syringe exchange programs--United States, 2002." *MMWR - Morbidity & Mortality Weekly Report* 54(27): 673-6.

Centers for Disease Control and Prevention (2007). *Syringe Exchange Programs - United States, 2005. MMWR Weekly Centers for Disease Control and Prevention*. 56: 1164-1167.

Centers for Disease Control and Prevention (2007). *Syringe exchange programs - United States, 2005. Morbidity and Mortality Weekly Report*. Atlanta. 56(44): 1164-1167.

Centers for Disease Control and Prevention (CDC) (2007). *Syringe exchange programs --- United States, 2005. Morbidity and Mortality Weekly Report*,. 56(44): 1164-1167.

Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." *Addiction* 104.

Friedman, S., B. Tempalski, et al. (2004). "Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users." *Journal of Urban Health* 81(3): 377-400.

Harris, Z. K. (2006). "Efficient allocation of resources to prevent HIV infection among injection drug users: the Prevention Point Philadelphia (PPP) needle exchange program." *Health Economics* 15(2): 147-58.

International Harm Reduction Association (IHRA) (2007). *Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland*.

Lifepoint (2005). *Outreach and syringe program guidelines and operating procedures*

New York City Commission (2005). *Report of the New York City Commission on HIV/AIDS: Recommendations to make NYC a national and global model for HIV/AIDS prevention, treatment, and care*. New York, New York City Commission: 51.

Office of AIDS California Department of public health (2008). *Syringe exchange programs in California: An overview*.

Prevention Point Philadelphia (2008). *Quarterly Service Data*.

Stozek, M. A., L. E. Taylor, et al. (2004). "Prescribing syringes to injection drug users with HIV: an important clinical and public health tool." *Journal of the Association of Nurses in AIDS Care* 15(2): 59-63.

Substance Abuse and Mental Health Services Administration Office of Applied Studies (2008). *National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on substance abuse treatment facilities. DASIS Series: S-44*. Rockville.

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
HIV among IDU prevalence estimate (%)	Low	Mid	High
Reference			
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
HIV among IDU prevalence estimate (%)	Low	Mid	High
Reference			
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	
Year of reported data	
Reference	

ARV: All documents reviewed

Celentano, D., N. Galai, et al. (2001). "Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users." *AIDS* 15(13): 1707-1715.

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	
Year	2007
Reference	See references for other Condom indicators

Condoms 2: Number of sites distributing condoms to IDUs

Data reported	99.2% of 131 NSP programs report distributing condoms to IDUs 186 NSPs in total in the country		
Year of reported data	2007		
Reference	Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." <i>Addiction</i> 104.		
Adjustments	Assumed 99.2% of all 186 NSPs nationally provide condoms to IDUs		
Final/Adjusted data (to be used as indicator numerator)	185		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	0.07	0.09	0.14

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2007		
Reference	Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." <i>Addiction</i> 104.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.67	0.96	1.34
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	203 946 878 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 366 500	1 960 000	2 733 000
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

Condoms: All documents reviewed

- Boutwell, A. and J. D. Rich (2004). "Syringe access for injection drug users in Rhode Island." *Medicine & Health, Rhode Island* 87(1): 15-6.
- Centers for Disease Control & Prevention (2007). "Syringe exchange programs--United States, 2005." *MMWR - Morbidity & Mortality Weekly Report* 56(44): 1164-7.
- Centers for Disease Control and Prevention (2005). "Update: syringe exchange programs--United States, 2002." *MMWR - Morbidity & Mortality Weekly Report* 54(27): 673-6.
- Centers for Disease Control and Prevention (2007). *Syringe Exchange Programs - United States, 2005. MMWR Weekly Centers for Disease Control and Prevention*. 56: 1164-1167.
- Centers for Disease Control and Prevention (2007). *Syringe exchange programs - United States, 2005. Morbidity and Mortality Weekly Report*. Atlanta. 56(44): 1164-1167.
- Centers for Disease Control and Prevention (CDC) (2007). *Syringe exchange programs --- United States, 2005. Morbidity and Mortality Weekly Report*,. 56(44): 1164-1167.
- Des Jarlais, D. C., C. McKnight, et al. (2009). "Doing harm reduction better: syringe exchange in the United States." *Addiction* 104.
- Lifepoint (2005). *Outreach and syringe program guidelines and operating procedures*